It was withdrawn from many developed markets in the early 1980s (in 1982 in the United States), being made a Schedule I drug in the U.S. in 1984.
It was withdrawn from many developed markets in the early 1980s. In the United States it was withdrawn in 1982 and made a Schedule I drug in 1984.